Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) and Royalty Pharma (NASDAQ:RPRX – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.
Insider & Institutional Ownership
86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
Milestone Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Milestone Pharmaceuticals | 1 | 1 | 4 | 1 | 2.71 |
| Royalty Pharma | 0 | 0 | 8 | 0 | 3.00 |
Milestone Pharmaceuticals currently has a consensus target price of $6.40, indicating a potential upside of 733.33%. Royalty Pharma has a consensus target price of $61.57, indicating a potential downside of 11.31%. Given Milestone Pharmaceuticals’ higher probable upside, research analysts plainly believe Milestone Pharmaceuticals is more favorable than Royalty Pharma.
Profitability
This table compares Milestone Pharmaceuticals and Royalty Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Milestone Pharmaceuticals | N/A | -288.33% | -58.27% |
| Royalty Pharma | 32.14% | 30.01% | 14.91% |
Valuation and Earnings
This table compares Milestone Pharmaceuticals and Royalty Pharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Milestone Pharmaceuticals | $1.55 million | 61.69 | -$63.06 million | ($0.69) | -1.11 |
| Royalty Pharma | $2.38 billion | 16.79 | $770.95 million | $1.45 | 47.88 |
Royalty Pharma has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Royalty Pharma beats Milestone Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
About Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
